Wipfli Financial Advisors’s Royalty Pharma RPRX Stock Holding History

Wipfli Financial Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$16K	Buy	+404	New	+$17.3K	﹤0.01%	1664

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SGA

Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return

Wipfli Financial Advisors's RPRX Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in Royalty Pharma (RPRX) in Q3 2022: 404 shares worth $16K. The stake represents ﹤0.01% of the portfolio and ranks #1664 among its holdings.

319 funds tracked by Wall St. Rank hold RPRX as of Q3 2022.

Wipfli Financial Advisors held 404 shares of Royalty Pharma worth $16K as of Q3 2022.
Royalty Pharma was a new Wipfli Financial Advisors position in Q3 2022.
Royalty Pharma made up ﹤0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #1664 holding.
319 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.